Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma

Autor: Dominique Maas, Britta Laros-van Gorkom, Sanne Gianotten, Marjan Cruijsen, Waander van Heerde, Marten Nijziel

Publikováno v: Case Reports in Hematology, Vol 2018 (2018)

We present a rare case of acquired von Willebrand syndrome (AVWS) caused by a mantle cell lymphoma. A 61-year-old male suffered from recurrent bleeding symptoms since a few months. Initially, physical examination was normal. von Willebrand factor ant

Externí odkaz: https://doaj.org/article/522fbaa5c4164ebaad7bd15279c16e07

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Autor: Marjan Cruijsen, Josephine M.I. Vos, Masja de Haas, Andrea Patriarca, Jorge J. Castillo, Liesbeth E M Oosten, Ramona Cassin, Shirley D'Sa, Bruno Fattizzo, Efstathios Kastritis, Henrik Frederiksen, Steven P. Treon, Marit Jalink, Despina Fotiou, Sigbjørn Berentsen

Publikováno v: Jalink, M, Berentsen, S, Castillo, J J, Treon, S P, Cruijsen, M, Fattizzo, B, Cassin, R, Fotiou, D, Kastritis, E, De Haas, M, Oosten, L E M, Frederiksen, H, Patriarca, A, D'Sa, S & Vos, J M I 2021, ' Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome ', Blood, vol. 138, no. 20, pp. 2002-2005 . https://doi.org/10.1182/blood.2021012039
Blood, 138(20), 2002-2005. American Society of Hematology

Cold antibody-mediated autoimmune hemolytic anemia (cAIHA) is a rare disease, usually related to an underlying indolent clonal B-cell lymphoproliferative disorder. Jalink and colleagues describe an international retrospective analysis of Bruton tyros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e46a0ab4453d3203d2376d3b047c01
https://hdl.handle.net/1887/3279923

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study

Autor: A.A. van de Loosdrecht, F. de Boer, Saskia K. Klein, J. Pruijt, B. de Valk, Edo Vellenga, B.P. van Rees, W.J.F.M. van der Velden, Leo F. Verdonck, Gerwin Huls, Marjan Cruijsen, Nicole M. A. Blijlevens, E. van der Spek, Mels Hoogendoorn, Y. Tromp, A.F.J. de Haan

Publikováno v: Leukemia & Lymphoma, 61(11), 2752-2755. TAYLOR & FRANCIS LTD
Leukemia & Lymphoma, 61, 2752-2755
Leukemia & Lymphoma, 61, 11, pp. 2752-2755
Leukemia and Lymphoma, 61(11), 2752-2755. Informa Healthcare
Cruijsen, M, van der Velden, W J F M, de Haan, A F J, Klein, S K, Hoogendoorn, M, Tromp, Y, de Valk, B, van Rees, B, de Boer, F, van der Spek, E, Pruijt, J, Verdonck, L F, Vellenga, E, Blijlevens, N, van de Loosdrecht, A A & Huls, G 2020, ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ', Leukemia and Lymphoma, vol. 61, no. 11, pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217

Several clinical studies have shown superiority of azacitidine compared to conventional care regimens in frail patients with MDS and AML [1–4]. However, clinical decision making with regards to dos...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f2ea5a8664a1f0d9ef5596b2925927
https://research.rug.nl/en/publications/6f589496-7d1d-40a0-a479-356e1e47405c

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation

Autor: Nicole M. A. Blijlevens, Hartmut Bertz, Robert Zeiser, Gerwin Huls, Reinhard Marks, Lioudmila Bogatyreva, Ralph Wäsch, Walter J.F.M. van der Velden, Rainer Claus, Justus Duyster, Jürgen Finke, Marjan Cruijsen, Sebastian Sommer, Michael Lübbert, Annette M. May

Publikováno v: Leukemia Research, 72, 20-26. PERGAMON-ELSEVIER SCIENCE LTD
Leukemia Research, 72, pp. 20-26
Leukemia Research, 72, 20-26

The combination of 5-azacytidine (AZA) with donor lymphocyte infusions (DLIs) can induce remissions in patients with relapsed myeloid malignancies after allo-HCT. As decitabine (DAC) is known to be effective also in AML/MDS with leukocytosis, we inve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e80fd7f4a7470b8eb5463a18f301db5e
https://doi.org/10.1016/j.leukres.2018.07.005

Clinical Results of Hypomethylating Agents in AML Treatment

Autor: Gerwin Huls, Michael Lübbert, Pierre W. Wijermans, Marjan Cruijsen

Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 4, Iss 1, Pp 1-17 (2014)

Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigeneti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f133298358abe09bae6c8876b9bbd2af
http://europepmc.org/articles/PMC4470235